Email this article IMMUNOLOGICAL EFFECT OF VACCINATION AGAINST PNEUMOCOCCAL INFECTION IN HIV-INFECTED CHILDREN
- Authors: Pakhomov D.V1,2,3,4, Kostinov M.P1,2,3,4, Poddubikov A.V1,2,3,4, Vaneeva N.P1,2,3,4, Snegova N.F1,2,3,4, Nikitina T.N1,2,3,4, Zinkina T.N1,2,3,4, Suloeva S.V1,2,3,4
-
Affiliations:
- Mechnikov Research Institute of Vaccines and Sera
- Institute of Immunology, Moscow
- Center for Control of HIV infection and AIDS, Kaliningrad
- Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Russia
- Issue: Vol 86, No 2 (2009)
- Pages: 48-52
- Section: Articles
- URL: https://microbiol.crie.ru/jour/article/view/13261
- ID: 13261
Cite item
Full Text
Abstract
Aim. To measure level of antibodies to pneumococcal antigens in HIV-infected children vaccinated in the age >2 y.o. in order to assess clinical effect of vaccination. Materials and methods. Levels of IgG and IgM were measured by ELISA in 16 HIV-infected children >24 months of age vaccinated against pneumococcal infection with Pneumo 23 vaccine on IIA-B stage of the disease. When the study was conducted, children did not receive antiretroviral therapy. Control group was represented by 47 children of the same age born from HIV-negative women. Results. It was determined that HIV-infected children had high baseline levels of IgG and IgM to antigens of Streptococcus pneumoniae to 2 years of age, which is indirect evidence of previous pneumococcal infection. Increase of antibody levels after vaccination to polysaccharides (PS) of S.pneumoniae serotypes 3, 6B, 9N, 23F as well as to mix of PS included in the vaccine was not observed compared to the control group. Despite the absence in dynamics of IgG and IgM levels, decrease of acute respiratory infections incidence on 34.6 — 36.4% was noted in HIV-infected participants during 1-year follow-up, which can be associated with immunocorrecting effect of PS contained in the Pneumo 23 vaccine. It was assumed that significant clinical and immunological effect of vaccination could be obtained by administration of pneumococcal conjugate vaccine in younger age, before realization of HIV-infection. Conclusion. Vaccination against pneumococcal infection is indicated for HIV-infected children; it promotes decrease of rate of intercurrent infections on the background of the main disease.
Full Text
ИММУНОЛОГИЧЕСКИЙ ЭФФЕКТ ВАКЦИНАЦИИ ПРОТИВ ПНЕВМОКОККОВОЙ ИНФЕКЦИИ У ВИЧ-ИНФИЦИРОВАННЫХ ДЕТЕЙ×
About the authors
D. V Pakhomov
Mechnikov Research Institute of Vaccines and Sera; Institute of Immunology, Moscow; Center for Control of HIV infection and AIDS, Kaliningrad; Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Russia
M. P Kostinov
Mechnikov Research Institute of Vaccines and Sera; Institute of Immunology, Moscow; Center for Control of HIV infection and AIDS, Kaliningrad; Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Russia
A. V Poddubikov
Mechnikov Research Institute of Vaccines and Sera; Institute of Immunology, Moscow; Center for Control of HIV infection and AIDS, Kaliningrad; Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Russia
N. P Vaneeva
Mechnikov Research Institute of Vaccines and Sera; Institute of Immunology, Moscow; Center for Control of HIV infection and AIDS, Kaliningrad; Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Russia
N. F Snegova
Mechnikov Research Institute of Vaccines and Sera; Institute of Immunology, Moscow; Center for Control of HIV infection and AIDS, Kaliningrad; Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Russia
T. N Nikitina
Mechnikov Research Institute of Vaccines and Sera; Institute of Immunology, Moscow; Center for Control of HIV infection and AIDS, Kaliningrad; Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Russia
T. N Zinkina
Mechnikov Research Institute of Vaccines and Sera; Institute of Immunology, Moscow; Center for Control of HIV infection and AIDS, Kaliningrad; Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Russia
S. V Suloeva
Mechnikov Research Institute of Vaccines and Sera; Institute of Immunology, Moscow; Center for Control of HIV infection and AIDS, Kaliningrad; Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Infectious Diseases, Russia
References
- Белошицкий Г.В. Эпидемиологическая характеристика пневмококковых менингитов. Автореф. дис. канд. мед. наук. М., 2005.
- Козлов P.C. Современные возможности специфической профилактики пневмококковых инфекций. Клин. микробиол. антимикроб. химиотерап. 2002, 4 (1): 61—69.
- Лукачев И.В. Специфический IgG-, IgE ответ и течение бронхиальной астмы у детей в процессе вакцинации препаратами «Pneumo-23» и «Act-HIB». Автореф. дис. канд. мед. наук. М., 2004.
- Покровский В.В. ВИЧ-инфекция в России: прогноз. Вопр. вирусол. 2004, 3: 31-34.
- Покровский В.В. Когда наступит перелом в борьбе с ВИЧ/СПИДом? Эпидемиол. инфекц. бол. 2006, 6: 4—7.
- Рыжов А.А. Применение вакцин «Pneumo-23» и «Act-HIB» в профилактике и лечении хронических заболеваний легких у детей. Автореф. дис. канд. мед. наук. М., 2004.
- Тарасова А.А. Состояние специфического иммунитета у детей с иммунопатологическими заболеваниями, вакцинированных в рамках календаря прививок, и клиникоиммунологический эффект бактериальной и гриппозной вакцин. Автореф. дис. д-ра мед. наук. Н. Новгород, 2006.
- Douglas D. Pneumococcal vaccine protective in HIV-infected children. Ann. Allergy Asthma Immunol. 2004, 92: 558—564.
- Draft Position Paper on pneumococcal vaccines. WHO/EURO document CMDS 01 01 02 5 October 1998.
- Gibb D., Spoulou V., Giacomelli A. et al. Antibody response to Haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection. Pediatr. Infect. Dis. J. 1995, 14: 129—135.
- Plouffe J., Breiman R., Facklam R. Bacteriemia with Streptococcus pneumoniae in adults: implication for therapy and prevention. JAMA. 1996, 275: 194—198.
- Tangsinmankong N., Kamchaisatin W., Day N.K. et al. Immunogenicity of 23-valent pneumococcal polysaccaride vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. Ann. Allergy Asthma Immunol. 2004, 92 (5): 558—564.
Supplementary files
